Many asthma patients experience persistent symptoms despite appropriate clinical and guideline-based treatment with inhaled corticosteroids

Journal of the American Academy of Nurse Practitioners

Volumn 19, Issue 9, 2007, Pages 459-470

  Mogil, Joan ^a  

^a Nassau Chest Physicians PC   (United States)

Author keywords

Asthma; GERD; Immunoglobulin E (IgE); Inhaled corticosteroids (ICS); Leukotriene modifiers; Long acting beta agonists (LABAs); Omalizumab; Patient education; Persistent symptoms; Rhinitis; Sinusitis; Treatment guidelines

Indexed keywords

ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; OMALIZUMAB;

ARTICLE; ASTHMA; CLINICAL PROTOCOL; COMORBIDITY; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; NURSE ATTITUDE; NURSE PRACTITIONER; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; RISK FACTOR; TREATMENT FAILURE; TREATMENT REFUSAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL PROTOCOLS; COMORBIDITY; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HUMANS; IMMUNOGLOBULIN E; LEUKOTRIENE ANTAGONISTS; NURSE PRACTITIONERS; NURSE'S ROLE; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT REFUSAL;

EID: 34548208586     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2007.00247.x     Document Type: Article

References (85)

1. Aaronson, D., Kaiser, H., Dockhorn, R., Findlay, S., Korenblat, P., Thorsson, L., et al 1998). Effects of budesonide by means of the Turbuhaler on the hypothalamic-pituitary-adrenal axis in asthmatic subjects: A dose response study. Journal of Allergy and Clinical Immunology, 101 (3 312 319.
2. Adams, C. D., Dreyer, M. L., Dinakar, C. Portnoy, J. M 2004). Pediatric asthma: A look at adherence from the patient and family perspective. Current Allergy and Asthma Reports, 4 (6 425 432.
3. Adams, N. P., Bestall, J. C., Lasserson, T. J. Jones, P. W 2005). Inhaled fluticasone proprionate versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews, 2, CD003135.
4. Adcock, I. M. Lane, S. J 2003). Mechanisms of steroid action and resistance in inflammation. Corticosteroid-insensitive asthma: Molecular mechanisms. Journal of Endocrinology, 178 (3 347 355.
5. American Lung Association Epidemiology and Statistics Unit, Research and Program Services 2005). Trends in asthma morbidity and mortality. San Diego, CA : Kintera.
6. Asthma in America 1998). Asthma in America survey slide kit. Retrieved June 8, 2007, from http://asthmainamerica.com.
7. Asthma Programs at Baylor: Asthma, Allergy, Immunology and Pulmonary. Baylor Healthcare Systems 2006). Rules of two. Retrieved from www.baylorhealthcare.com/medicalspecialties/asthma/asthmaprograms.htm#Rof2
8. Bateman, E. D., Boushey, H. A., Bousquet, J., Busse, W. W., Clark, T. J., Pauwels, R. A., et al 2004). Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. American Journal of Respiratory and Critical Care Medicine, 170 (8 836 844.
9. Bender, B. G. Bender, S. E 2005). Patient-identified barriers to asthma treatment adherence: Responses to interviews, focus-groups, and questionnaires. Immunology and Asthma Clinics of North America, 25 (1 107 130.
10. Boulet, L. P., Phillips, R., O'Byrne, P. Becker, A 2002). Evaluation of asthma control by physician and patients: Comparison with current guidelines. Canadian Respiratory Journal, 9 (6 417 423.
11. Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., et al 2005). The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy, 60 (3 302 308.
12. Broide, D. H 2001). Molecular and cellular mechanisms of allergic disease. Journal of Allergy and Clinical Immunology, 108 (Suppl. 2 S65 S71.
13. Buhl, R., Solèr, M., Matz, J., Townley, R., O'Brien, J., Noga, O., et al 2002). Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. European Respiratory Journal, 20 (1 73 78.
14. Burrows, B., Martinez, F. D., Halonen, M., Barbee, R. A. Cline, M. G 1989). Association of asthma with serum IgE levels and skin-test reactivity to allergens. New England Journal of Medicine, 320 (5 271 277.
15. Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., et al 2001). Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. Journal of Allergy and Clinical Immunology, 108 (2 184 190.
16. Centers for Disease Control 2003). Self-reported asthma prevalence and control among adults - United States, 2001. Morbidity and Mortality Weekly Report, 52 (17 381 384.
17. Chan, M. T. S., Leung, D. Y. M., Szefler, S. J. Spahn, J. D 1998). Difficult-to-control asthma: Clinical characteristics of steroid-insensitive asthma. Journal of Allergy and Clinical Immunology, 101 (5 594 601.
18. Cochrane, M. G., Bala, M. V., Downs, K. E., Mauskopf, J. Ben-Joseph, R. H 2000). Inhaled corticosteroids for asthma therapy: Patient compliance, devices, and inhalation technique. Chest, 117 (2 542 550.
19. Currie, G. P., Lee, D. K. Srivastava, P 2005). Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest, 128 (4 2954 2962.
20. Currie, G. P., Srivastava, P., Dempsey, O. J. Lee, D. K 2005). Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. QJM, 98 (3 171 182.
21. Deniz, Y. M. Gupta, N 2005). Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clinical Reviews in Allergy and Immunology, 29 (1 31 48.
22. Dolan, C. M., Fraher, K. E., Bleeker, E. R., Borish, L., Chipps, B., Hayden, M. L., et al 2004). Design and baseline characteristics of The Epidemiology and Natural History of Asthma Outcomes and Treatment Regimens (TENOR) study: A large cohort of patients with severe or difficult-to-treat asthma. Annals of Allergy, Asthma, & Immunology, 92 (1 32 39.
23. Drazen, J. M., Yandava, C. N., Dubé, L., Szczerback, N., Hippensteel, R., Pillari, A., et al 1999). Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genetics, 22 (2 168 170.
24. Ducharme, F. M. Di Salvio, F 2004). Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews, 2, CD002314.
25. Ferreira, M. A. R 2004). Inflammation in allergic asthma: Initiating events, immunological response and risk factors. Respirology, 9 (1 16 24.
26. Finn, A., Gross, G., van Bavel, J., Lee, T., Windom, H., Everhard, F., et al 2003). Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. Journal of Allergy and Clinical Immunology, 111 (2 278 284.
27. Fukushima, C., Matsuse, H., Tomari, S., Obase, Y., Miyazaki, Y., Shimoda, T., et al 2003). Oral candidiasis associated with inhaled corticosteroid use: Comparison of fluticasone and beclomethasone. Annals of Allergy, Asthma, & Immunology, 90 (6 646 651.
28. Gelber, L. E., Seltzer, L. H., Bouzoukis, J. K., Pollart, S. M., Chapman, M. D. Platts-Mills, T. A. E 1993). Sensitization and exposure to indoor allergens as risk factors for asthma among patients presenting to hospital. American Review of Respiratory Disease, 147 (3 573 578.
29. Genentech Inc 2003). Xolair (omalizumab). Product information. South San Francisco, CA : Genentech Inc.
30. Gern, J. E. Busse, W. W 1999). Association of rhinovirus infection with asthma. Clinical Microbiology Reviews, 12 (1 9 18.
31. Global Initiative for Asthma 2005). Pocket guide for asthma management and prevention (NIH Publication No. 02-3659). Update from NHLBI/WHO workshop report: Global strategy for asthma management and prevention, 2002. Bethesda, MD : National Heart, Lung, and Blood Institute, National Institutes of Health.
32. Global Initiative for Asthma 2006). Global strategy for asthma management and prevention (NIH Publication No. 02-3659). Bethesda, MD : National Heart, Lung, and Blood Institute, National Institutes of Health.
33. Goldman, D. P., Joyce, G. F., Escarce, J. J., Pace, J. E., Solomon, M. D., Laouri, M., et al 2004). Pharmacy benefits and the use of drugs by the chronically ill. Journal of the American Medical Association, 291 (19 2344 2350.
34. Harding, S. M 2005). Gastroesophageal reflux: A potential asthma trigger. Immunology and Asthma Clinics of North America, 25 (1 131 148.
35. Heaney, L. G. Robinson, D. S 2005). Severe asthma treatment: Need for characterising patients. Lancet, 365 (9463 974 976.
36. Holgate, S. T., Chuchalin, A. G., Hébert, J., Lotvall, J., Persson, G. B., Chung, K. F., et al 2004). Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and Experimental Allergy, 34 (4 632 638.
37. Hubbard, R. B., Smith, C. J. P., Smeeth, L., Harrison, T. W. Tattersfield, A. E 2002). Inhaled corticosteroids and hip fracture: A population-based case-control study. American Journal of Respiratory and Critical Care Medicine, 166 (112, Pt. 1 1563 1566.
38. In, K. H., Asano, K., Beier, D., Grobholz, J., Finn, P. W., Silverman, E. K., et al 1997). Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. Journal of Clinical Investigation, 99 (5 1130 1137.
39. Israel, E., Chinchilli, V. M., Ford, J. G., Boushey, H. A., Cherniack, R., Craig, T. J., et al 2004). Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet, 364 (9444 1505 1512.
40. Israel, E., Cohn, J., Dubé, L. Drazen, J. M 1996). Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. Journal of the American Medical Association, 275 (12 931 936.
41. Israel, E., Drazen, J. M., Liggett, S. B., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., et al 2000). The effect of polymorphisms of the ß2-adrenergic receptor on the response to regular use of albuterol in asthma. American Journal of Respiratory and Critical Care Medicine, 162 (1 75 80.
42. Johnston, S. L., Pattermore, P. K., Sanderson, G., Smith, S., Lampe, F., Josephs, L., et al 1995). Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. British Medical Journal, 310 (6989 1225 1229.
43. Jónasson, G., Carlsen, K-H., Sodal, A., Jonasson, C. Mowinckel, P 1999). Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. European Respiratory Journal, 14 (1 150 154.
44. Kemp, J. P 2005). Comparison of Zileuton and placebo: Acute and sustained pulmonary effects in moderate and severe asthmatics. Abstract (B36, Poster G57) presented at the American Thoracic Society 2005 International Conference, San Diego, CA, May 20-25, 2005.
45. Kerkhoff, M., Dubois, A. E. J., Postma, D. S., Schouten, J. P. de Monchy, J. G. R 2003). Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy, 58 (9 905 911.
46. Kiljander, T. O. Laitinen, J. O 2004). The prevalence of gastroesophageal reflux disease in adult asthmatics. Chest, 126 (5 1490 1494.
47. Lanier, B. Q., Corren, J., Lumry, W., Liu, J., Fowler-Taylor, A. Gupta, N 2003). Omalizumab is effective in the long-term control of severe allergic asthma. Annals of Allergy Asthma and Immunology, 91 (2 154 159.
48. Lantz, C. S., Yamaguchi, M., Oettgen, H. C., Katona, I. M., Miyajima, I., Kinet, J. P., et al 1997). IgE regulates mouse basophil Fc epsilon RI expression in vivo. Journal of Immunology, 158 (6 2517 2521.
49. Lee, D. K., Currie, G. P., Hall, I. P., Lima, J. J. Lipworth, B. J 2004). The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. British Journal of Clinical Pharmacology, 57 (1 68 75.
50. Lee, D. K. C., Jackson, C. M., Bates, C. E. Lipworth, B. J 2004). Cross tolerance to salbutamol occurs independently of ß2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol. Thorax, 59 (8 662 667.
51. Leung, D. Y. M., Spahn, J. D. Szefler, S. J 2001). Steroid resistant asthma: New insights and implications for management. In S. J. Szefler D. Y. M. Leung (Eds Severe asthma: A multidisciplinary approach (2nd ed., pp. 597 619). New York : Marcel Dekker.
52. Lipworth, B. J 1999). Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Archives of Internal Medicine, 159 (9 941 955.
53. Masoli, M., Holt, S., Weatherall, M. Beasley, R 2004a). Dose-response relationship of inhaled budesonide in adult asthma: A meta-analysis. European Respiratory Journal, 23 (4 552 558.
54. Masoli, M., Holt, S., Weatherall, M. Beasley, R 2004b). The dose-response relationship of inhaled corticosteroids in asthma. Current Allergy and Asthma Reports, 4 (2 144 148.
55. Masoli, M., Weatherall, M., Holt, S. Beasley R 2004). Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax, 59 (1 16 20.
56. Message, S. D. Johnston, S. L 2001). The immunology of virus infection in asthma. European Respiratory Journal, 18 (6 1013 1025.
57. Morris, L. S. Schulz, R. M 1993). Medication compliance: The patient's perspective. Clinical Therapy, 15 (3 593 606.
58. National Asthma Education and Prevention Program 1997). Expert panel report 2: Guidelines for the diagnosis and management of asthma (NIH Publication No. 97-4051). Bethesda, MD : National Heart, Lung, and Blood Institute.
59. National Asthma Education and Prevention Program 2003). Expert panel report: Guidelines for the diagnosis and management of asthma. Update on selected topics 2002 (NIH Publication No. 02-5074). Bethesda, MD : National Heart, Lung, and Blood Institute.
60. Nelson, H. S 2005). Zileuton improves daily and nocturnal symptoms compared to placebo in moderate and severe asthmatics. Abstract (B36, Poster G68) presented at the American Thoracic Society 2005 International Conference, San Diego, CA, May 20-25, 2005.
61. Niebauer, K., Dewilde, S., Fox-Rushby, J. Revicki, D. A 2006). Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Annals of Allergy Asthma and Immunology, 96 (2 316 326.
62. Peachell, P 2005). Targeting the mast cell in asthma. Current Opinion in Pharmacology, 5 (3 251 256.
63. Pollart, S. M., Chapman, M. D., Fiocco, G. P., Rose, G. Platt-Mills, T. A. E 1989). Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. Journal of Allergy and Clinical Immunology, 83 (5 875 882.
64. Rabe, K. F., Vermeire, P. A., Soriano, J. B. Maier, W. C 2000). Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study. European Respiratory Journal, 16 (5 802 807.
65. Rosenwasser, L. J., Klemm, J. D., Klemm, D. J., Drazen, J. M., Burchard, E. G. Leung, D. Y. M 2001). Association of asthmatic steroid insensitivity with an Il-4 gene promoter polymorphism. Journal of Allergy and Clinical Immunology, 107, S235.
66. Rosenwasser, L. J. Nash, D. B 2003). Incorporating omalizumab into asthma treatment guidelines: Consensus panel recommendations. Pharmacy & Therapeutics, 28, 400 414.
67. Ruigómez, A., Rodríguez, L. A. G., Wallander, M.-A., Johansson, S., Thomas, M. Price, D 2005). Gastroesophageal reflux disease and asthma. A longitudinal study in UK general practice. Chest, 128 (1 85 93.
68. Salpeter, S. R., Ormiston, T. M. Salpeter, E. E 2004). Meta-analysis: Respiratory tolerance to regular ß2 agonist use in patients with asthma. Annals of Internal Medicine, 140 (10 802 813.
69. Sharpe, M. Jarvis, B 2001). Inhaled mometasone furoate: A review of its use in adults and adolescents with persistent asthma. Drugs, 61 (11 1325 1350.
70. Smith, D. H., Malone, D. C., Lawson, K. A., Okamoto, L. J., Battista, C. Saunders, W. B 1997). A national estimate of the economic costs of asthma. American Journal of Respiratory and Critical Care Medicine, 156 (3, Pt. 1 787 793.
71. Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., et al 2001). The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. European Respiratory Journal, 18 (2 254 261.
72. Sporik, R., Holgate, S. T., Platts-Mills, T. A. Cogswell, J. J 1990). Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. New England Journal of Medicine, 323 (8 502 507.
73. Szefler, S. J., Martin, R. J., King, T. S., Boushey, H. A., Cherniack, R. M., Chinchilli, V. M., et al 2002). Significant variability in response to inhaled corticosteroids for persistent asthma. Journal of Allergy and Clinical Immunology, 109 (3 410 418.
74. Tan, W. C 2005). Viruses in asthma exacerbations. Current Opinion in Pulmonary Medicine, 11 (1 21 26.
75. Tantisira, K. G., Lake, S., Silverman, E. S., Palmer, L. J., Lazarus, R., Silverman, E. K., et al 2004). Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Human Molecular Genetics, 13 (13 1353 1359.
76. Tashkin, D. P., Rand, C., Nides, M., Simmons, M., Wise, R., Coulson, A. H., et al 1991). A nebulizer chronolog to monitor compliance with inhaler use. American Journal of Medicine, 91 (4A 33S 36S.
77. Taylor, D. R., Drazen, J. M., Herbison, G. P., Yandava, C. N., Hancox, R. J. Town, G. I 2000). Asthma exacerbations during long term ß agonist use: Influence of ß2 adrenoceptor polymorphism. Thorax, 55 (9 762 767.
78. Taylor, M. R. G. Bristow, M. R 2004). The emerging pharmacogenomics of the beta-adrenergic receptors. Congestive Heart Failure, 10 (6 281 288.
79. Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F., Jr., Boushey, H. A., Deykin, A., et al 2005). β-adrenergic receptor polymorphisms and response to salmeterol. American Journal of Respiratory and Critical Care Medicine, 173 (5 519 526.
80. Weinstein, A. G 2005). Should patients with persistent severe asthma be monitored for medication adherence? Annals of Allergy, Asthma, and Immunology, 94 (2 251 257.
81. Weir, T. D., Mallek, N., Sandford, A. J., Bai, T. R., Awadh, N., Fitzgerald, J. M., et al 1998). β2-Adrenergic receptor haplotypes in mild, moderate, and fatal/near fatal asthma. American Journal of Respiratory and Critical Care Medicine, 158 (3 787 791.
82. Welch, M. J., Levy, S., Smith, J. A., Feiss, G. Farrar, J. R 1997). Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest, 112 (3 597 606.
83. Williamson, I. J., Matusiewicz, S. P., Brown, P. H., Greening, A. P. Crompton, G. K 1995). Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. European Respiratory Journal, 8 (4 590 592.
84. Wolfenden, L. L., Diette, G. B., Krishnan, J. A., Skinner, E. A., Steinwachs, D. M. Wu, A. W 2003). Lower physician estimate of underlying asthma severity leads to undertreatment. Archives of Internal Medicine, 163 (2 231 236.
85. Yamaguchi, M., Sayama, K., Yano, K., Lantz, C. S., Noben-Trauth, N., Ra, C., et al 1999). IgE enhances Fcε receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: Synergistic effect of IL-4 and IgE on human mast cell Fcε receptor I expression and mediator release. Journal of Immunology, 162 (9 5455 5465.